Study of BMS-790052 plus Peg-Interferon alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with HIV and HCV

-
Investigator: Anne F. Luetkemeyer, MD
Sponsor: Bristol-Myers Squibb Company

Location(s): France; Germany; Italy; Russia; Spain; United Kingdom; Argentina; Puerto Rico; Canada; Australia

Description

The purpose of this open label study is to evaluate the safety and efficacy of BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in untreated Hepatitis C Patients Coinfected with HIV Virus compared to historic controls.  Official Title: A Phase 3, Open Label Study of Safety and Efficacy With BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected With Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV)